Video

Dr. Hiddemann on Updated Results of Immunochemotherapy Study in Follicular Lymphoma

Author(s):

Wolfgang Hiddemann, MD, PhD
Conference|European Hematology Association Congress

Wolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.

Wolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.

Updated results of this international trial comparing obinutuzumab (Gazyva) and rituximab (Rituxan) in patients with previously untreated patients with follicular lymphoma were presented at the 2017 European Hematology Association Congress.

These updates confirmed that the obinutuzumab combination had significantly higher progression-free survival compared with rituximab. The different chemotherapy backbones were also discussed in further detail, says Hiddemann.

Related Videos
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
Breelyn Wilky, director, Sarcoma Medical Oncology, The Cheryl Bennett and McNeilly Family Endowed Chair in Sarcoma Research, deputy associate director, Clinical Research, associate professor, medicine, medical oncology, the University of Colorado Medicine
Eric Jonasch, MD, professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Grzegorz S. Nowakowski, MD
T. Jeroen N. Hiltermann, MD, of University of Groningen
Related Content
Elacestrant plus abemaciclib in breast cancer | Image Credit: © Axel Kock - stock.adobe.com
September 18th 2024

Elacestrant Plus Abemaciclib Demonstrates Clinical Benefit in Pretreated ER+/HER2– Metastatic Breast Cancer

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Anna Dańska-Bidzińska, MD, a gynecologist from Warsaw Medical University in Warsaw, Poland
September 18th 2024

Lenvatinib Plus Pembrolizumab Affords Deep and Durable Responses in Endometrial Cancer

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Renal Cell Carcinoma | Image Credit: © Crystal light - stock.adobe.com
September 17th 2024

Ipilimumab Plus Nivolumab Increases 12-Month OS Rate vs SOC in nccRCC

Xinan Sheng, MD, of Peking University Cancer Hospital and Institute
September 17th 2024

Benmelstobart Plus Anlotinib Demonstrates Efficacy in Frontline Advanced RCC